China adds 51 innovative Class 1 drugs to 2026 national medical insurance list

The record share of Class 1 innovative drugs in the reimbursement list signals that China's payer is increasingly willing to fund domestically developed innovation, not just me-too therapies. That matters most for local biotechs whose commercial case has hinged on reimbursement access, and for the hospitals and patients in oncology, rare disease and mental health who gain covered options. The open question is whether this inclusion translates into actual volume and pricing pressure at the hospital level, and whether the commercial insurance catalog becomes a meaningful second channel alongside basic coverage.